Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

4405 ARTÍCULOS , VIENDO DEL 2941 AL 2955

Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances

Sciascia S, Amigo MC, Roccatello D, Khamashta M.

Nat Rev Rheumatol. 2017 Sep;13(9):548-560. doi: 10.1038/nrrheum.2017.124. Epub 2017 Aug 3.

Editorial: Ubiquitin and the Brain: Roles of Proteolysis in the Normal and Abnormal Nervous System

Hegde AN, van Leeuwen FW.

Front Mol Neurosci. 2017 Jul 18;10:220. doi: 10.3389/fnmol.2017.00220. eCollection 2017.

Differences in Dihydrotetrabenazine Isomer Concentrations Following Administration of Tetrabenazine and Valbenazine

Skor H, Smith EB, Loewen G, O'Brien CF, Grigoriadis DE, Bozigian H.

Drugs R D. 2017 Sep;17(3):449-459. doi: 10.1007/s40268-017-0202-z.

Body weight is a robust predictor of clinical progression in Huntington disease

van der Burg JMM, Gardiner SL, Ludolph AC, Landwehrmeyer GB, Roos RAC, Aziz NA.

Ann Neurol. 2017 Sep;82(3):479-483. doi: 10.1002/ana.25007. Epub 2017 Aug 22.

Losing ground: Frontostriatal atrophy disrupts language embodiment in Parkinson's and Huntington's disease

Birba A, García-Cordero I, Kozono G, Legaz A, Ibáñez A, Sedeño L, García AM.

Neurosci Biobehav Rev. 2017 Sep;80:673-687. doi: 10.1016/j.neubiorev.2017.07.011. Epub 2017 Aug 2.

Melatonin as a mitochondrial protector in neurodegenerative diseases

Wongprayoon P, Govitrapong P.

Cell Mol Life Sci. 2017 Nov;74(21):3999-4014. doi: 10.1007/s00018-017-2614-x. Epub 2017 Aug 8.

Induced neural stem cells as a means of treatment in Huntington's disease

Choi KA, Hong S.

Expert Opin Biol Ther. 2017 Nov;17(11):1333-1343. doi: 10.1080/14712598.2017.1365133. Epub 2017 Aug 9.

Receptors make the pathway choice for protein degradation

Feng Y, Klionsky DJ.

Autophagy. 2017 Oct 3;13(10):1617-1618. doi: 10.1080/15548627.2017.1356553. Epub 2017 Aug 10.

Evolving Motivations: Patients' and Caregivers' Perceptions About Seeking Myotonic Dystrophy (DM1) and Huntington's Disease Care

LaDonna KA, Watling CJ, Ray SL, Piechowicz C, Venance SL.

Qual Health Res. 2017 Sep;27(11):1727-1737. doi: 10.1177/1049732317711901. Epub 2017 Jun 19.

Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1)

Bresciani A, Missineo A, Gallo M, Cerretani M, Fezzardi P, Tomei L, Cicero DO, Altamura S, Santoprete A, Ingenito R, Bianchi E, Pacifici R, Dominguez C, Munoz-Sanjuan I, Harper S, Toledo-Sherman L, Park LC.

Arch Biochem Biophys. 2017 Oct 1;631:31-41. doi: 10.1016/j.abb.2017.08.003. Epub 2017 Aug 8.

Nonmotor Symptoms in Huntington Disease

Cardoso F.

Int Rev Neurobiol. 2017;134:1397-1408. doi: 10.1016/bs.irn.2017.05.004. Epub 2017 Jun 1.

Atypical presentation of anti-N-methyl-D-aspartate receptor encephalitis: two case reports

Maggio MC, Mastrangelo G, Skabar A, Ventura A, Carrozzi M, Santangelo G, Vanadia F, Corsello G, Cimaz R.

J Med Case Rep. 2017 Aug 16;11(1):225. doi: 10.1186/s13256-017-1388-y.

Are Astrocytes the Predominant Cell Type for Activation of Nrf2 in Aging and Neurodegeneration?

Liddell JR.

Antioxidants (Basel). 2017 Aug 18;6(3):65. doi: 10.3390/antiox6030065.

Novel mutations in PANK2 and PLA2G6 genes in patients with neurodegenerative disorders: two case reports

Dastsooz H, Nemati H, Fard MAF, Fardaei M, Faghihi MA.

BMC Med Genet. 2017 Aug 18;18(1):87. doi: 10.1186/s12881-017-0439-y.

Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's Disease

McGarry A, Kieburtz K, Abler V, Grachev ID, Gandhi S, Auinger P, Papapetropoulos S, Hayden M.

J Huntingtons Dis. 2017;6(3):189-199. doi: 10.3233/JHD-170241.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias